{
    "ticker": "KTRA",
    "name": "Kintara Therapeutics, Inc.",
    "description": "Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer. Established in 2018, Kintara aims to address unmet medical needs in oncology by leveraging a proprietary drug delivery platform and targeted therapies. The company's lead product candidates, VAL-083 and KTRA-101, are designed to treat various forms of cancer, including glioblastoma multiforme (GBM) and other solid tumors. VAL-083, a small molecule that acts as a DNA-targeting agent, is currently being evaluated in clinical trials for its efficacy in treating GBM, a notoriously aggressive cancer with limited treatment options. Kintara is committed to advancing its pipeline through rigorous clinical research and collaboration with leading cancer centers, with the goal of providing better outcomes for patients. The company is dedicated to innovation and strives to improve the quality of life for cancer patients through its focused research and development efforts. Kintara Therapeutics continues to explore new therapeutic approaches and optimize existing treatments, reflecting its mission to transform cancer care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2018",
    "website": "https://www.kintaratherapeutics.com",
    "ceo": "Dr. Saad A. Shah",
    "social_media": {
        "twitter": "https://twitter.com/KintaraTX",
        "linkedin": "https://www.linkedin.com/company/kintara-therapeutics/"
    },
    "investor_relations": "https://www.kintaratherapeutics.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Saad A. Shah",
            "position": "CEO"
        },
        {
            "name": "Dr. Howard A. T. McLeod",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "VAL-083",
                "KTRA-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kintara Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Kintara Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments including VAL-083 and KTRA-101.",
        "keywords": [
            "Kintara",
            "Cancer Treatment",
            "VAL-083",
            "KTRA-101",
            "Oncology",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Kintara Therapeutics focus on?",
            "answer": "Kintara Therapeutics focuses on the development of innovative therapies for the treatment of cancer."
        },
        {
            "question": "What are Kintara's lead product candidates?",
            "answer": "Kintara's lead product candidates are VAL-083 and KTRA-101."
        },
        {
            "question": "Where is Kintara headquartered?",
            "answer": "Kintara is headquartered in San Diego, California, USA."
        },
        {
            "question": "When was Kintara Therapeutics founded?",
            "answer": "Kintara Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "CLVS",
        "KOD",
        "NDAQ"
    ],
    "related_stocks": [
        "AMGN",
        "MRNA",
        "GILD",
        "BMY"
    ]
}